广济药业
(000952)
| 流通市值：19.13亿 | | | 总市值：19.13亿 |
| 流通股本：3.44亿 | | | 总股本：3.44亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 435,445,077.49 | 311,953,896.27 | 163,094,175.38 | 623,974,702.31 |
| 营业收入 | 435,445,077.49 | 311,953,896.27 | 163,094,175.38 | 623,974,702.31 |
| 二、营业总成本 | 524,257,326.7 | 378,715,465.03 | 199,970,058.28 | 796,334,880.55 |
| 营业成本 | 316,774,988.46 | 239,423,706.92 | 126,495,001.14 | 458,170,823.18 |
| 税金及附加 | 14,926,153.88 | 9,349,202.67 | 4,953,672.82 | 17,385,085.77 |
| 销售费用 | 18,959,886.13 | 13,500,406.89 | 5,978,335.57 | 29,472,099.11 |
| 管理费用 | 115,550,333.59 | 75,063,254.74 | 43,784,621.42 | 198,688,187.27 |
| 研发费用 | 22,954,279.59 | 16,911,190.51 | 5,704,542.27 | 41,910,370.26 |
| 财务费用 | 35,091,685.05 | 24,467,703.3 | 13,053,885.06 | 50,708,314.96 |
| 其中:利息费用 | 31,489,396.16 | 21,715,071.11 | 11,649,218.55 | 51,155,779.37 |
| 其中:利息收入 | 731,470.24 | 423,248.03 | 179,388.59 | 1,025,058.05 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -781,280.09 | -668,417.79 | -359,666.95 | 18,384,643.69 |
| 资产处置收益 | 27,173,110.47 | 5,903,843.56 | - | 549,256.12 |
| 资产减值损失(新) | -4,228,983.35 | -3,197,373.67 | 777,558.1 | -290,117,682.92 |
| 信用减值损失(新) | -638,049.34 | 200,984.87 | 876,079.46 | -9,730,806.21 |
| 其他收益 | 3,941,379.98 | 3,252,615.89 | 1,245,128.66 | 9,571,904.52 |
| 四、营业利润 | -63,346,071.54 | -61,269,915.9 | -34,336,783.63 | -443,702,863.04 |
| 加:营业外收入 | 970,942.41 | 178,311.92 | 4,667.67 | 2,845,098.11 |
| 减:营业外支出 | 409,682.72 | 47,190.18 | 16,846.19 | 2,246,591.81 |
| 五、利润总额 | -62,784,811.85 | -61,138,794.16 | -34,348,962.15 | -443,104,356.74 |
| 减:所得税费用 | 2,858,806.34 | 762,840.69 | -541,713.49 | -4,157,232.19 |
| 六、净利润 | -65,643,618.19 | -61,901,634.85 | -33,807,248.66 | -438,947,124.55 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -65,643,618.19 | -61,901,634.85 | -33,807,248.66 | -438,947,124.55 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -59,905,882.98 | -57,945,128.17 | -31,643,613.3 | -404,494,390.01 |
| 少数股东损益 | -5,737,735.21 | -3,956,506.68 | -2,163,635.36 | -34,452,734.54 |
| 扣除非经常损益后的净利润 | -87,092,707.53 | -65,588,662.16 | -32,684,784.09 | -412,685,662.25 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.17 | -0.17 | -0.09 | -1.16 |
| (二)稀释每股收益 | -0.17 | -0.17 | -0.09 | -1.15 |
| 八、其他综合收益 | 13,415.68 | 10,234.37 | 6,670.7 | 217.12 |
| 归属于母公司股东的其他综合收益 | 13,415.68 | 10,234.37 | 6,670.7 | 217.12 |
| 九、综合收益总额 | -65,630,202.51 | -61,891,400.48 | -33,800,577.96 | -438,946,907.43 |
| 归属于母公司股东的综合收益总额 | -59,892,467.3 | -57,934,893.8 | -31,636,942.6 | -404,494,172.89 |
| 归属于少数股东的综合收益总额 | -5,737,735.21 | -3,956,506.68 | -2,163,635.36 | -34,452,734.54 |
| 公告日期 | 2026-10-30 | 2026-08-28 | 2026-04-25 | 2026-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |